Why did RXRX stock drop? — 2026-11-19

Research session: 2026-11-19. Published: 2026-11-19T21:33:32.668090+00:00.

Final report

RXRX — Recursion Pharmaceuticals, Inc. - Class A Common Stock

Session close: $2.72. Regular-session share volume: 46,905,025. Change from previous close: -3.72%.

Key developments

Morgan Stanley kept a Hold rating on Recursion Pharmaceuticals but cut its price target, signaling a less favorable view of the company's market position and outlook. The update offers a cautious analyst stance rather than a change in conviction, so investors weighing the stock face a tempered valuation signal from a major research firm.

Company news Morgan Stanley Maintains Hold Rating on Recursion Pharmaceuticals, Lowers Price Target

News sources

Company news Morgan Stanley Maintains Hold Rating on Recursion Pharmaceuticals, Lowers Price Target

Full report for 2026-11-19